Ethnic Bridging: The Who, the When, the Why
In the dynamic realm of clinical drug development, a new star is rising: Ethnic Bridging clinical trials, also known as ethnobridging or Asian bridging...
News at CenExel
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...
The Placebo-Control Reminder Script and Supplementary Instrument Properties: Evaluation of Face and Content Validity
CenExel is proud to highlight the poster presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Scientific Meeting, February 2023, Washington,...
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal,...
Primer on the Autonomic Nervous System – 4th Edition
This book provides a concise and accessible overview of autonomic neuroscience for students, scientists, and clinicians.
CenExel CNS Opens Center in Los Alamitos, California
Los Alamitos, November 29, 2022 /GlobeNewswire/ — CenExel CNS announces the grand opening of the newest clinical research facility in Los Alamitos, California. CenExel CNS...
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry led-study in subjects with schizophrenia and healthy volunteers.
Further Exploration of the Placebo-Control Reminder Script: Essential Perspectives from the End User
CenExel is proud to highlight the poster presented at the Annual CNS Summit, November 2022, Boca Raton, FL. ABSTRACT Introduction: Placebo and nocebo responses continue...
CenExel Acquires Apex Innovative Sciences
Salt Lake City, June 16, 2022 /GlobeNewswire/ — CenExel announces the acquisition of Apex Innovative Sciences, parent company of Collaborative Neuroscience Research (CNS) and Hassman...